6 ms·
Researchers uncover on/off switch for breast cancer metastasis in mice
- ugh123 3y ago[flagged]
- pavel_lishin 3y ago> I like to get GPT-4 output for certain things like this to understand certain aspects of it (and not assuming everything it tells me is fact). I've been downvoted before for this but here goes... You likely get downvoted because you post things verbatim that you acknowledge may not be true, without actually bothering to fact-check the output.
- msie 3y agoWell then, I expect a therapy real soon now.
- steve_taylor 3y agoIt'll be here any decade now.
- cameronh90 3y agoWhile this particular treatment may go nowhere, cancer treatment has come a LONG way recently. Lots of theoretical “in mice” treatments I recall reading about 5-10 years ago are now actively being deployed clinically. By some measures we’ve had more than a 25% drop in age+health standardised cancer mortality over the last decade. It’s easy to feel cynical when so many things seem like they get stuck for ages in trials and never make it to an actual treatment, but modern medicine is truly amazing. I have family who are sadly no longer with us, but who likely would have been cured completely if they had developed the same cancer today.
- gizmo686 3y agoLooking at this graph of breast cancer mortality, the drop has been significant, steady, and showing no sign of leveling off. https://seer.cancer.gov/statistics-network/explorer/application.html?site=55&data_type=2&graph_type=1&compareBy=sex&chk_sex_3=3&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0 https://seer.cancer.gov/statistics-network/explorer/applicat...
- AlexErrant 3y agoA caveat for the rest of the world: > our finding showed a significant increase in breast cancer mortality rate in the world during the past 25 years ... Statistical analysis showed a significant increase for breast cancer mortality rate in all super regions, except for High-income super region. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745227/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745227/ and for women under 40: > Female breast cancer mortality rates have stopped declining in women younger than 40 years, ending a trend that existed from 1987 to 2010. Conversely, mortality rates have continued to decline in women aged 40–79 years. https://pubs.rsna.org/doi/full/10.1148/radiol.2021203476 https://pubs.rsna.org/doi/full/10.1148/radiol.2021203476
- TheCapeGreek 3y agoThe conclusion I'd come to from those quotes is all these "amazing breakthroughs" might be in use sure, but not to the scale (and price) a layman would expect in order for it to be a properly viable solution for many sufferers.
- jrpt 3y agoI agree that there's been some progress in therapies and robot-assisted surgery, but the reason for the improvement in mortality seems more to do with early detection. Cancer deaths overall are also improving due to fewer smokers, but that should be accounted for by "health standardized" measurements. I think this paper explains it: https://pubmed.ncbi.nlm.nih.gov/27175568/ https://pubmed.ncbi.nlm.nih.gov/27175568/ "the major factors that accounted for these favorable trends were progress in tobacco control and improvements in early detection and treatment" I feel like the treatment progress for most metastatic solid cancers have not significantly improved. A significant improvement wouldn't be just improving overall survival by a year or so. What seems possible to achieve (someday soon perhaps) is making cancer either a manageable condition, like HIV now is, or curable.
- mbreese 3y agoENPP1 is a known target that has been under active investigation for many years. This press release would like for you to think this Stanford lab discovered it, but it’s been known about for a while. We are just now starting to understand more about how it works in cancer (this work is a part of that). But treatments are already being worked on using this pathway.
- wbkang 3y agoThis is not an informed comment. New immunotherapies for cancers are real. It's just that they are very expensive. But it's not right to claim they are very far or imaginative.
- iwontberude 3y agoBut are there therapies for mice?
- microtherion 3y agoI'm afraid I don't share your optimistic view. This being the US, I expect a bidding war on whether the switch should be set to "ON" or "OFF".
- voz_ 3y agoThis is the dumbest conspiracy ever, stop propagating it.
- adamredwoods 3y agoBased from another study: >> Patients with high ENPP1 levels had low response to pembrolizumab and high chance of metastases. Those with low ENPP1 levels had a high response to pembrolizumab and no metastases. ENPP1 predicted both response to immunotherapy and likelihood of relapse. Keytruda/PD-1 blocker: https://en.wikipedia.org/wiki/Pembrolizumab https://en.wikipedia.org/wiki/Pembrolizumab ENPP1 blockers already exist: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e14550 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e1...
- superb_dev 3y agoFrom the article: > This means that clinicians can use ENPP1 levels to better determine appropriate treatment for breast cancer patients. It also means that drugs that destroy the ENPP1 dam could make existing therapies more effective – and several ENPP1 inhibitors are already in clinical development.
- jseliger 3y agoAt least one ENPP1 blocker appears to be in clinical trials already: https://clinicaltrials.gov/study/NCT05270213?term=RBS2418&rank=2 https://clinicaltrials.gov/study/NCT05270213?term=RBS2418&ra.... It lists "advanced cancers" as being eligible. I'm most interested in head and neck cancers, and pembrolizumab (Keytruda) is only effective in 20 - 30% of patients; see e.g. https://ascopubs.org/doi/full/10.1200/JCO.21.02198 https://ascopubs.org/doi/full/10.1200/JCO.21.02198: "In the phase Ib KEYNOTE-012 study of pembrolizumab monotherapy in R/M HNSCC (N = 192), objective response rate (ORR) was higher in patients with PD-L1 CPS ≥ 1 than CPS < 1 (21% v 6%; one-sided P = .023)." A lot of oncologists I've talked to also think PD-L1 expression is overrated as a marker of pembro effectiveness; obviously there's something going on, with higher PD-L1 expression being net better in terms of pembro utility overall, but the data are noisy and lots of exceptions abound. I'm also not sure how reliable PD-L1 expression tests are. My tumor was tested once by a well-known-in-the-field company called CARIS, and it showed a 20% Combined Positive Score (CPS). Another test done by the Mayo Clinic showed a 5% score. Who's right? Who knows. No one I've talked to. The attitude seems to be that no one is convinced the PD-L1 tests are highly accurate, and that once the CPS is above 1%, pembro's effectiveness is a crapshoot anyway. I got five doses of pembro and failed it, utterly.
- epistasis 3y ago> Li began collaborating with two professors at the University of San Francisco: Hani Goodarzi, also an incoming Arc Institute Core Investigator, and Laura Van’t Veer, a clinician who leads the I-SPY 2 Trial, a groundbreaking breast cancer trial. These famous researchers are actually at UCSF, not University of San Francisco. UCSF is really a leader in breast cancer the world over, far more influential than Stanford's much smaller amount of faculty on the topic. So it's a bit weird to see such a basic mistake.
- BarryMilo 3y agoI wonder if journnalists used to actually do research
- boulos 3y agoIt seems to be a typo. The credits at the bottom state: > Additional co-authors are from the University of California, San Francisco, and Arc.
- pfisherman 3y agoFor those who are not familiar, the I-SPY 2 trial is quite remarkable. It is an adaptive trial design - in essence reinforcement learning with human experiments.[1] For all the criticism FDA gets, they should also get credit for leaning into new approaches to testing drugs like adaptive trials. Part of why the US remains one of the most innovative countries. 1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731787/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731787/
- ldoughty 3y agoTo summarize -- They found a correlation between a protein (ENPP1) and breast cancer metastasis that they feel is a very strong signaler for pembrolizumab immunotherapy resistance. This would be helpful information to help get to the right dosage of medicine faster (or skip a class of drugs entirely), which might save weeks or months of taking a drug that effectively is neutralized by the resistance. Additionally, hopefully new medicine will (after more research) go after this protein and see if attacking it allows the immune system to better resist cancer itself. It's also worth noting that two of the researchers involved in this work own a company to try to utilize patents around this work.
- voisin 3y ago> It's also worth noting that two of the researchers involved in this work own a company to try to utilize patents around this work. Is the implication that there is bias, or are you implying there is reason to be hopeful that it makes it to market quickly?
- fnorder 3y agoWhy not both?
- ldoughty 3y agoI was stating a fact presented at the end of the article. The interpretation of that fact is up to the reader.
- alehlopeh 3y agoYou said it was worth noting, which is more than just stating a fact.
- Retric 3y agoFacts can be seen as important without implying any specific interpretation of them. I consider the speed of light being 299,792 km per second as worth remembering even if I have no specific use in mind.
- pmoriarty 3y ago...in mice
- SV_BubbleTime 3y agoIf we just experimented on and killed lots of humans we would be both further ahead and behind.
- oooyay 3y agoidk why I see so many comments like this on the medical threads of HN lately. Laboratory mice are close enough to us to do testing on and have provided reliable results throughout their use. A basic Wikipedia search shows references for all of those claims and more: https://en.wikipedia.org/wiki/Laboratory_mouse https://en.wikipedia.org/wiki/Laboratory_mouse
- mbreese 3y agoIt’s a common trope in the field that we’ve already cured cancer in mice. They are similar enough to be a useful model for study. However, they are still quite different to the point where you never quite know how treatments will react… especially in cancer. The biggest issue is that the mice we use for research typically have no or a highly depleted immune system. One of the biggest breakthroughs in the cancer field (IMO) is the development of humanized mice. These are mice that have had their immune system genes replaced with the human versions of these genes. This is incredibly important for work like this where you’re studying cancer cell-immune cell interactions.
- glenstein 3y agoHave we actually cured cancer in mice?
- lossolo 3y agoWhat I'm really curious about is how many of these experiments and trials didn't work in mice but would work in humans.
- davidw 3y agoI'm going to go with "off". Thanks.
- ThinkBeat 3y agoSide issue: Some people must have industrial scale production of mice to be used in experiments. How far are we from being able to model an entire mouse? The last I heard was that someone could map all of a small worm, so a mouse is magnitudes more complicated than that. But compute power increases.
- peteradio 3y agoIf you're thinking we could test pharmaceuticals in a simulation I think thats a long way off. The worm model is not sufficient to model chemical reactions/lifecycles.
- aeyes 3y agoLink to the research article: https://www.pnas.org/doi/10.1073/pnas.2313693120 https://www.pnas.org/doi/10.1073/pnas.2313693120 Also note that this isn't exactly news, it's been an ongoing research topic for a few years. Here is a research article from 2022: https://aacrjournals.org/cancerdiscovery/article/12/5/1356/694562/Tumor-ENPP1-CD203a-Haptoglobin-Axis-Exploits https://aacrjournals.org/cancerdiscovery/article/12/5/1356/6...